Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Key Points

• Satellos will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP trial of forazapadin, following discussions with the FDA. The study will compare 60-mg and 120-mg treatment arms with placebo and assess safety and tolerability.
• The company expects top-line results from the 12-week placebo-controlled period in Q1 2027. Satellos says statistically significant fat-fraction results linked to clinical function could support an accelerated-approval pathway, but the FDA has not determined that the study would be sufficient for approval.
• Satellos cited an open-label study in four adults, where mean biceps muscle fat fraction fell 3.7 percentage points after five months, as preliminary support. The company cautioned that the small study was not designed to establish efficacy and expects 12-month data later in 2026.

Satellos Bioscience NASDAQ: MSLE said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living with Duchenne muscular dystrophy, following a Type C interaction with the U.S. Food and Drug Administration.

The company expects to report top-line results from the study’s 12-week placebo-controlled period in the first quarter of 2027. Satellos believes positive fat-fraction data that correlate with clinical function could support a potential accelerated approval pathway, subject to further data and regulatory review.

“We have selected fat fraction alongside safety and tolerability, as we believe it is an objective and potentially clinically meaningful measure of forazapadin’s effect in Duchenne,” said Frank Gleeson, Satellos’ co-founder and chief executive officer.

Study to Assess Muscle Composition and Function

BASECAMP will measure changes in fat fraction in the vastus lateralis, a thigh muscle. Chief Medical Officer Dr. Wildon Farwell said fat fraction rises as damaged muscle is replaced by fat and that natural history studies have associated increases with worsening function and earlier loss of ambulation.

At 12 weeks, Satellos plans to compare MRI results for participants receiving forazapadin with those receiving placebo. The analysis is expected to include all randomized participants and assess both the 60-milligram and 120-milligram treatment arms, along with safety and tolerability.

The company also plans to report available data on timed function tests, strength and biomarkers, as well as six-month data from participants who have reached that milestone. Functional assessments include stride velocity, time to rise, a four-stair climb and dynamometry. Farwell said the study will also evaluate a regenerative index using muscle biopsies.

Farwell said the FDA discussion addressed the relationship between fat fraction and clinical endpoints without specifying a required degree of change. He said the agency did not express concern about BASECAMP’s size or conduct, but did not describe an FDA determination that the study would be sufficient for approval.

In response to an analyst’s question about a roughly 1.3% difference between treatment and placebo, Farwell said that range was consistent with the company’s thinking and could allow the study to show statistical significance. He said a statistically significant difference in fat fraction correlated with clinical function would provide the clearest potential path to accelerated approval, in the company’s view.

Earlier Study Offered Preliminary Support

Satellos pointed to results from TRAILHEAD, an open-label study in four adults with Duchenne, as preliminary support for its approach. After five months of treatment, mean biceps brachii fat fraction fell from 49.7% to 46%, an absolute reduction of 3.7 percentage points, Farwell said. Each participant showed a decline.

The reduction was accompanied by increased upper-limb total effort, maintained improvement in hand grip strength and generally stable upper-extremity function after six months of exposure, he said. Farwell cautioned that TRAILHEAD was small and was not designed to establish efficacy. Satellos expects 12-month data from its four participants later in 2026.

Gleeson said the company plans to provide guidance in the first quarter of 2027 on its intentions for a potential filing and commercialization after it has data to analyze.

About Satellos Bioscience (NASDAQ:MSLE)

Satellos Bioscience Inc is a biotechnology company focused on developing regenerative medicines for muscle-related diseases and disorders. The company's research centers on muscle satellite cells, a type of stem cell responsible for repairing and regenerating skeletal muscle after injury or disease.

Satellos is developing small-molecule therapies intended to restore or enhance the natural muscle-regeneration process by correcting impaired satellite-cell function. Its lead program, SAT-3247, is being investigated as an orally administered potential treatment for muscle-wasting conditions, including Duchenne muscular dystrophy.

Founded in Canada, Satellos Bioscience conducts research and drug-development activities from its Canadian operations while pursuing treatments intended for patients in international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.